Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Down 5.7 %

Shares of Aptevo Therapeutics stock opened at $0.34 on Friday. Aptevo Therapeutics has a 1-year low of $0.34 and a 1-year high of $33.67. The company’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $77.78.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.